Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
EMBO Rep ; 25(3): 1387-1414, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38347224

ABSTRACT

Understanding how chromatin organisation is duplicated on the two daughter strands is a central question in epigenetics. In mammals, following the passage of the replisome, nucleosomes lose their defined positioning and transcription contributes to their re-organisation. However, whether transcription plays a greater role in the organization of chromatin following DNA replication remains unclear. Here we analysed protein re-association with newly replicated DNA upon inhibition of transcription using iPOND coupled to quantitative mass spectrometry. We show that nucleosome assembly and the re-establishment of most histone modifications are uncoupled from transcription. However, RNAPII acts to promote the re-association of hundreds of proteins with newly replicated chromatin via pathways that are not observed in steady-state chromatin. These include ATP-dependent remodellers, transcription factors and histone methyltransferases. We also identify a set of DNA repair factors that may handle transcription-replication conflicts during normal transcription in human non-transformed cells. Our study reveals that transcription plays a greater role in the organization of chromatin post-replication than previously anticipated.


Subject(s)
Chromatin , RNA Polymerase II , Animals , Humans , RNA Polymerase II/metabolism , DNA Replication , Nucleosomes , Transcription Factors/metabolism , Chromatin Assembly and Disassembly , Mammals/genetics , Mammals/metabolism
2.
Nature ; 627(8002): 204-211, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38383787

ABSTRACT

Targeted protein degradation is a pharmacological modality that is based on the induced proximity of an E3 ubiquitin ligase and a target protein to promote target ubiquitination and proteasomal degradation. This has been achieved either via proteolysis-targeting chimeras (PROTACs)-bifunctional compounds composed of two separate moieties that individually bind the target and E3 ligase, or via molecular glues that monovalently bind either the ligase or the target1-4. Here, using orthogonal genetic screening, biophysical characterization and structural reconstitution, we investigate the mechanism of action of bifunctional degraders of BRD2 and BRD4, termed intramolecular bivalent glues (IBGs), and find that instead of connecting target and ligase in trans as PROTACs do, they simultaneously engage and connect two adjacent domains of the target protein in cis. This conformational change 'glues' BRD4 to the E3 ligases DCAF11 or DCAF16, leveraging intrinsic target-ligase affinities that do not translate to BRD4 degradation in the absence of compound. Structural insights into the ternary BRD4-IBG1-DCAF16 complex guided the rational design of improved degraders of low picomolar potency. We thus introduce a new modality in targeted protein degradation, which works by bridging protein domains in cis to enhance surface complementarity with E3 ligases for productive ubiquitination and degradation.


Subject(s)
Drug Design , Proteolysis , Substrate Specificity , Ubiquitin-Protein Ligases , Ubiquitination , Bromodomain Containing Proteins/metabolism , Cell Cycle Proteins/metabolism , Proteasome Endopeptidase Complex/metabolism , Proteolysis Targeting Chimera , Transcription Factors/metabolism , Ubiquitin-Protein Ligases/metabolism , Protein Binding , Protein Domains
SELECTION OF CITATIONS
SEARCH DETAIL